/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
Dual pathway inhibitor therapy switched from dual antiplatelet therapy reduces risk of recurrent in-stent occlusion after endovascular therapy for femoropopliteal in-stent occlusion.
Event: ESC Congress 2023
Topic: Pharmacotherapy
Session: Arterial occlusive disease: a chronic pandemic needing attention to detail
